Bioanalytical Methods for Characterization of <scp>CAR‐T</scp> Cellular Kinetics: Comparison of <scp>PCR</scp> Assays and Matrices

Madhan Masilamani(National Institutes of Health), Sekhar Surapaneni(Bristol-Myers Squibb (United States)), Alice Park(Bristol-Myers Squibb (Germany)), Vibha Jawa(Bristol-Myers Squibb (Germany)), Carol Gleason(Bristol-Myers Squibb (United States)), Yan‐Shan Dai(Central South University), Johanna Mora(Bristol-Myers Squibb (United States)), Fan Wu(Jinan University), Xirong Zheng(Bristol-Myers Squibb (Germany)), Manisha Lamba(Bristol-Myers Squibb (Germany)), Edwin Lu(Bristol-Myers Squibb (United States)), Romita Das(Bristol-Myers Squibb (Germany)), Tim Mack(Bristol-Myers Squibb (Germany))

Clinical Pharmacology & Therapeutics

July 9, 2023

10.1002/cpt.2991

Cited by 12

Related Papers

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper

|Molecular Therapy — Methods & Clinical Development|2022|113

CD94/NKG2A Inhibits NK Cell Activation by Disrupting the Actin Network at the Immunological Synapse

|The Journal of Immunology|2006|103

2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)

|Bioanalysis|2019|94

2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)

|Bioanalysis|2021|60

Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays

|mAbs|2021|57